Placeholder

FACULTY

Agustin Garcia

Professor - Clinical Medicine
Section Chief- Hematology Oncology

Hematology Oncology

Academic Office:

LSUHSC School of Medicine 
1700 Tulane Av, Room 502
New Orleans, LA 70112

504-568-2329

 

Clinical Office:

University Medical Center, Cancer Center
2001 Tulane Avenue
New Orleans, LA 70112

504-702-5700

 

Bio

Dr. Agustin Garcia is originally from Mexico and earned his Medical Degree from Universidad Anahuac in Mexico City. He completed his internship and residency training in Internal Medicine at the University of Illinois and a Fellowship in Medical Oncology at the University of Southern California.  He is board certified in Medical Oncology. Dr. Garcia's primary clinical and research interests focus on women’s cancers (particularly breast and ovarian cancer) and drug development. Prior to relocating to New Orleans he practiced at the University of Southern California as Director of Clinical Research for the Women’s Cancer Program. He currently serves as Section Chief of Hematology and Oncology at Louisiana State University in New Orleans where he holds the Charles W McMullin III and Richard Paul Grace Chair in Cancer Research.  Dr. Garcia is a member of the Breast Cancer Working Group and the Breast Cancer Committee in the Southwest Oncology Group and the Ovarian Cancer Committee of the NRG Oncology Group. He is conducting studies in breast and ovarian cancer evaluating new agents with novel mechanisms of action. He is a member of the American Society of Clinical Oncology, American Society of Breast Disease, European Society of Medical Oncology, and the NCI Task Force on Cervical Cancer. His work has been published in various journals such as the New England Journal of Medicine, Journal of Clinical Oncology and Gynecologic Oncology. He is a frequent speaker at local, national and international events.

Education

Medical:
M.D.
Universidad Anahuac
Mexico City, Mexico

Residency:
Internal Medicine
University of Ilinois at Urbana Champaign
Champaign County, Illinios

Fellowship:
Oncology
University of Southern California
Los Angeles, California 

Graduate:
Masters in Medical Management
University of Southern California
Los Angeles, California 

Affiliated Hospitals & Clinics

  • University Medical Center
  • East Jefferson General Hospital
  • Lallie Kemp Regional Medical Center
  • West Jefferson Medical Center

Publications

1. Pahlawanian AM, Norris VA, Jernigan AM, Morrell B, Morrell M, Nair N, Karamanis AM, Dauchy EM, Loch MM, Garcia AA. An Update on Screening and Prevention for Breast and Gynecological Cancers in Average and High Risk Individuals. Am J Med Sci. 2020 Nov;360(5):489-510. doi: 10.1016/j.amjms.2020.06.008. Epub 2020 Jun 10. Review. PubMed PMID: 32912601.

2. Wu AH, Tseng C, Vigen C, Yu Y, Cozen W, Garcia AA, Spicer D. Gut microbiome associations with breast cancer risk factors and tumor characteristics: a pilot study. Breast Cancer Res Treat. 2020 Jul;182(2):451-463. doi: 10.1007/s10549-020-05702-6. Epub 2020 May 28. PubMed PMID: 32468338; PubMed Central PMCID: PMC7297869.

3. Kumthekar P, Tang SC, Brenner AJ, Kesari S, Piccioni DE, Anders C, Carrillo J, Chalasani P, Kabos P, Puhalla S, Tkaczuk K, Garcia AA, Ahluwalia MS, Wefel JS, Lakhani N, Ibrahim N. ANG1005, a Brain-Penetrating Peptide-Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clin Cancer Res. 2020 Jun 15;26(12):2789-2799. doi: 10.1158/1078-0432.CCR-19-3258. Epub 2020 Jan 22. PubMed PMID: 31969331.

4. Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. PubMed PMID: 32314030; PubMed Central PMCID: PMC7188725.

5. Vergote I, Powell MA, Teneriello MG, Miller DS, Garcia AA, Mikheeva ON, Bidzinski M, Cebotaru CL, Dutcus CE, Ren M, Kadowaki T, Funahashi Y, Penson RT. Second-line lenvatinib in patients with recurrent endometrial cancer. Gynecol Oncol. 2020 Mar;156(3):575-582. doi: 10.1016/j.ygyno.2019.12.039. Epub 2020 Jan 17. PubMed PMID: 31955859.

6. Blake EA, Bradley CA, Mostofizadeh S, Muggia FM, Garcia AA, Roman LD, Matsuo K. Efficacy of pegylated liposomal doxorubicin maintenance therapy in platinum-sensitive recurrent epithelial ovarian cancer: a retrospective study. Arch Gynecol Obstet. 2019 Jun;299(6):1641-1649. doi: 10.1007/s00404-019-05104-0. Epub 2019 Mar 1. PubMed PMID: 30824986; PubMed Central PMCID: PMC7521082.

7. Moore HCF, Unger JM, Phillips KA, Boyle F, Hitre E, Moseley A, Porter DJ, Francis PA, Goldstein LJ, Gomez HL, Vallejos CS, Partridge AH, Dakhil SR, Garcia AA, Gralow JR, Lombard JM, Forbes JF, Martino S, Barlow WE, Fabian CJ, Minasian LM, Meyskens FL, Gelber RD, Hortobagyi GN, Albain KS. Final Analysis of the Prevention of Early Menopause Study (POEMS)/SWOG Intergroup S0230. J Natl Cancer Inst. 2019 Feb 1;111(2):210-213. doi: 10.1093/jnci/djy185. PubMed PMID: 30371800; PubMed Central PMCID: PMC6657277.

8. Rustin G, Vergote I, Micha JP, Duska LR, Reed N, Bendell J, Spitz D, Dark G, Hoch U, Tagliaferri M, Hannah AL, Garcia AA. A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer. Gynecol Oncol. 2017 Nov;147(2):276-282. doi: 10.1016/j.ygyno.2017.08.026. Epub 2017 Sep 19. PubMed PMID: 28935273.

9. Somlo G, Frankel PH, Arun BK, Ma CX, Garcia AA, Cigler T, Cream LV, Harvey HA, Sparano JA, Nanda R, Chew HK, Moynihan TJ, Vahdat LT, Goetz MP, Beumer JH, Hurria A, Mortimer J, Piekarz R, Sand S, Herzog J, Van Tongeren LR, Ferry-Galow KV, Chen AP, Ruel C, Newman EM, Gandara DR, Weitzel JN. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline BRCA1- or BRCA2-Associated Metastatic Breast Cancer: California Cancer Consortium Trial NCT01149083. Clin Cancer Res. 2017 Aug 1;23(15):4066-4076. doi: 10.1158/1078-0432.CCR-16-2714. Epub 2017 Mar 29. PubMed PMID: 28356425; PubMed Central PMCID: PMC5540749.

10. Connolly RM, Li H, Jankowitz RC, Zhang Z, Rudek MA, Jeter SC, Slater SA, Powers P, Wolff AC, Fetting JH, Brufsky A, Piekarz R, Ahuja N, Laird PW, Shen H, Weisenberger DJ, Cope L, Herman JG, Somlo G, Garcia AA, Jones PA, Baylin SB, Davidson NE, Zahnow CA, Stearns V. Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clin Cancer Res. 2017 Jun 1;23(11):2691-2701. doi: 10.1158/1078-0432.CCR-16-1729. Epub 2016 Dec 15. PubMed PMID: 27979916; PubMed Central PMCID: PMC5457329.

View Full List of publications

Research

Title: Enabling A Paradigm Shift: A Preference-Tolerant RCT of Personalized vs Annual Screening of Breast Cancer. SPEC-18-006               
Sponsor: BCRF via Quantum Leap Healthcare Collaborative
Role: Local Primary Investigator
Dates: 10/01/2018-12/30/2019

Title: IGF-2 in Herceptin refractory HER2-positive breast cancer
Sponsor: METAvivor Founders Award 
Role: Co-Investigator. (Bolin L) 

Title: Differential effects of diet on normal and malignant tissues
Sponsor: Obesity / Cancer Pilot and Feasibility Grant sponsored by the Pennington Nutrition Obesity Research Center (NORC) and LSU HSC-NO Cancer Center
Role: Co-Investigator. (Gilmore A, Kern L) 
Dates: 2017-2019

Title: Extending the Diversity, Reach, and Generalizability of the WISDOM Study. R01 PA-18-559 .
Sponsor: NIH
Role: Co-Investigator. (Esserman)
Dates: 09/01/2019-8/31/2024

 

Clinical Trials

Title: A Phase II Trial Assessing the Accuracy of Tumor Bed Biopsies in Predicting Pathologic Response in Patients with Clinical/Radiologic Complete Response After Neoadjuvant Chemotherapy in Order to Explore the Feasibility of Breast Conserving Treatment Without Surgery.
Sponsor: NCI

Title: A phase 1, open-label, dose-escalation study to evaluate the safety and tolerability of SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer.
Sponsor: Seattle Genetics

Title: Testing if docetaxel or paclitaxel induces less peripheral neuropathy in African American women
Sponsor: NCI

Title: A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy Versus Radiotherapy Alone for Inflammatory Breast Cancer
Sponsor: NCI

Title: (CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer)
Sponsor: NCI

Title: The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Sponsor: NCI

Title: A Phase 1/2a Evaluation of the Safety and Efficacy of Adding AL3818, a Dual Receptor Tyrosine Kinase Inhibitor, to Standard Platinum-Based Chemotherapy in Subjects with Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma
Sponsor: Advenchen

Title: A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients with Recurrent, Metastatic or Persistent Cervical Carcinoma
Sponsor: Iovance Therapeutics

Title: Testing the Addition of Two Approved Drugs, Olanzapine or Prochlorperazine, for Persistent Nausea
Sponsor: NCI

Title: A Prospective Observational Cohort Study to Develop A Predictive Model of Taxane-Induced Peripheral Neuropathy in Cancer Patients
Sponsor: NCI